Haemoglobinopathies Market Trends, Price, Demand, Analysis and Forecasts to 2022

According to Stratistics MRC, the Global Hemoglobinopathie market is accounted for $4.6 billion in 2015 and is expected to reach $8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022. Increasing incidences of hemoglobin disorders with strong product portfolio for sickle cell anemia such as HQK-1001 and Luspatercept, government’s awareness programs and advanced diagnostics and therapeutics will fuel the market growth. Research & development and growth across developed and developing economies will provide opportunity for the market growth. Instrumentation cost and expertise required for LC MS/MS, molecular identification of the alpha and beta chain mutations are some of the factors that impede the market growth.

Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period. The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market. Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth.

Browse full report with TOC@ https://marketreportscenter.com/reports/415448/haemoglobinopathies-global-market-outlook-2016-2022

Some of the key players in global Hemoglobinopathie market are Gamida Cell,Alnylam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma.

Disorders Covered:

Sickle Cell Disease

Haemoglobin variants diseases

o Haemoglobin C disease

o Haemoglobin S-C disease

Thalassemia

Drugs Covered:

NiCord

ZFP Transcription Factors

ALN-TMP

Drug Targeting PRMT5...